衰老基因表达特征与卒中患者90天结局
研究纳入129例≥60岁急性缺血性卒中患者和41名年龄性别匹配的对照,采用全血基因表达微阵列评估衰老特征富集,发现高衰老特征与90天改良Rankin量表(mRS)评分更差相关(OR 2.32;95%CI 1.05-5.97),提示血细胞衰老可能影响卒中功能结局。
要点
- 高衰老基因特征与卒中后90天更差mRS独立相关。
- 衰老特征随年龄增长,但不同年龄间存在变异。
- EGFR配体双调蛋白、表皮调节素及CCL16在结局组间差异显著。
核心结论
- 衰老特征表达增高与急性缺血性卒中后90天功能结局更差相关。
研究设计与样本
- 研究从University of Alberta Hospital招募129例≥60岁急性缺血性卒中患者和41名有卒中危险因素、年龄性别相似的对照,用微阵列测全血基因表达并以基因集富集分析量化衰老特征。
主要发现
- 结局差(mRS>2)的患者较结局好(mRS≤2)者衰老基因表达富集。
- 校正年龄、性别、卒中严重程度和2型糖尿病后,高衰老与mRS评分更差相关(OR 2.32;95%CI 1.05-5.97)。
- 结局组间差异表达最显著的衰老相关基因包括EGFR配体双调蛋白、表皮调节素和CCL16。
临床怎么用
- 测量血细胞衰老特征可能反映影响卒中功能结局的生物学衰老过程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Understanding the biological determinants of stroke outcome is essential to improve treatment strategies. Cellular senescence may contribute to vascular dysfunction with age and has been linked to poor outcomes across a range of diseases. However, the role of senescence on stroke outcome in patients is not well defined. We sought to investigate the relationship between enriched senescence-associated gene signature expression and functional outcome after stroke. METHODS: Acute ischemic stroke patients and control participants were recruited from University of Alberta Hospital. Control (non-stroke) participants had stroke risk factors and were of similar age and sex to the stroke patients. Whole-blood gene expression was measured by microarray. Senescence signature expression was evaluated to quantify senescence enrichment by gene set enrichment analysis. Outcome was determined using the modified Rankin Scale (mRS) at 90 days after stroke onset. The relationship between senescence, age, risk factors, and stroke outcome was analyzed through ordinal logistic regression. RESULTS: We included 129 acute ischemic stroke patients ≥60 years old, with a mean age of 77.3 ± 9.9 years and 41.9% female, and 41 control participants, with a mean age of 76.5 ± 7.9 years and 56.1% female. Patients with poor outcome (mRS > 2) had enriched senescence gene expression compared with those with good outcome (mRS ≤ 2); control participants also showed significant differences in senescence enrichment compared with the stroke outcome groups. High senescence was associated with a shift toward worse mRS scores (OR: 2.32; 95% CI 1.05-5.97) adjusted for age, sex, stroke severity, and type 2 diabetes mellitus. Senescence increased with age with variability across different ages. Among the senescence-associated genes, most differentially expressed between outcome groups were the epidermal growth factor receptor (EGFR) ligands amphiregulin and epiregulin, and the C-C motif chemokine ligand 16. DISCUSSION: Increased senescence was associated with worse stroke outcome. These findings suggest that blood cell senescence may contribute to vascular aging and worse stroke outcome, likely by altering epidermal growth factor receptor signaling, increasing inflammation and blood-brain barrier disruption. This study provides translational evidence that measuring senescence may reflect a biological aging process that influences functional outcome after stroke.
引用
- Real MGC, Zhang Y, Falcione SR, et al. Senescence Gene Expression Profiles and 90-Day Outcome in Stroke Patients. Neurology. 2026. PMID: 42479998. doi:10.1212/WNL.0000000000218295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。